Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2023 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Cash from Financing Activities of $14.7 million for Q4 2025, up 13242.71% year-over-year from N/an in Q4 2024, and up 350.65% quarter-over-quarter from $3.3 million in Q3 2025.
Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Cash from Financing Activities for 3 consecutive years, with $14.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 13242.71% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $18.6 million (up 134.36% YoY), while the FY2025 annual figure was $1.5 million, down 89.88% from the prior year.
- Cash from Financing Activities rose to $14.7 million in Q4 2025 per NEUP's latest filing, from $3.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $14.7 million in Q4 2025 and bottomed at -$227338.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $3.5 million across 3 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 137.11% — and 2025, when it surged 13242.71%.
- Neuphoria Therapeutics' Cash from Financing Activities stood at $5.6 million in 2023, then plunged by 101.98% to -$111562.0 in 2024, then soared by 13242.71% to $14.7 million in 2025.
- Business Quant data shows NEUP's Cash from Financing Activities at $14.7 million in Q4 2025, $3.3 million in Q3 2025, and $704675.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.66 Mn |
| Dec 31, 2025 | 14.66 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | 704,675.00 |
| Jun 30, 2025 | 704,675.00 |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | -111,562.00 |
| Dec 31, 2024 | -111,562.00 |
| Sep 30, 2024 | -227,338.00 |
| Sep 30, 2024 | -227,338.00 |
| Jun 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Sep 30, 2023 | 612,538.00 |
| Sep 30, 2023 | 612,538.00 |